Stock listing
Hamburg:3371 Corbus Pharmaceuticals Holdings, Inc. Aktie
German listing (Hamburg) of Corbus Pharmaceuticals Holdings, Inc. · home listing NASDAQ:CRBP
Follow Corbus Pharmaceuticals Holdings, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CRBP
$2.06 USD -0.38 (-15.4%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRBP
- Day range
- $2.01 – $2.48 USDNov 20, 2026
- Volume
- 1.38M sharesNov 20, 2026
- Market cap
- $42.45M USDAt the close on Nov 20, 2026 · price × 20.61M shares outstanding
- 52-week range
- $2.01 – $12.88 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $6.72M USDMedian day 790,150 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRBP · Home | $2.06 USD | -0.375 (-15.4%) | 1,380,532 | $2.43 | $2.48 | $2.01 | $2.435 | Close on Nov 20, 2026 |
| LSE:0SZI | $2.16 USD | -0.36 (-14.3%) | 21,596 | $2.39 | $2.45 | $2.12 | $2.52 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRBP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.06 | -0.375 | -15.4% | $2.43 | $2.48 | $2.01 | 1,380,532 | |
| $2.435 | -0.31 | -11.3% | $2.72 | $2.88 | $2.415 | 660,429 | |
| $2.745 | -0.265 | -8.8% | $2.96 | $3.003 | $2.62 | 635,314 | |
| $3.01 | -0.365 | -10.8% | $3.29 | $3.34 | $2.953 | 570,863 | |
| $3.375 | -0.015 | -0.4% | $3.41 | $3.62 | $3.00 | 953,696 | |
| $3.39 | -0.02 | -0.6% | $3.38 | $3.53 | $3.27 | 573,400 | |
| $3.41 | -0.59 | -14.7% | $4.00 | $4.01 | $3.23 | 1,050,900 | |
| $4.00 | +0.07 | +1.8% | $4.04 | $4.20 | $3.80 | 670,800 | |
| $3.93 | +0.41 | +11.6% | $3.39 | $3.98 | $3.21 | 643,000 | |
| $3.52 | +0.45 | +14.7% | $3.11 | $3.745 | $3.11 | 1,243,300 | |
| $3.07 | +0.21 | +7.3% | $2.93 | $3.125 | $2.91 | 685,200 | |
| $2.86 | -0.71 | -19.9% | $3.57 | $3.57 | $2.81 | 1,356,300 | |
| $3.57 | -0.30 | -7.8% | $3.97 | $4.099 | $3.57 | 2,012,100 | |
| $3.87 | -0.045 | -1.1% | $3.92 | $4.11 | $3.73 | 4,367,600 | |
| $3.915 | -0.305 | -7.2% | $4.21 | $4.23 | $3.895 | 673,200 | |
| $4.22 | 0.00 | 0.0% | $4.20 | $4.31 | $3.95 | 2,317,200 | |
| $4.22 | -0.03 | -0.7% | $4.25 | $4.34 | $4.10 | 1,482,200 | |
| $4.25 | +0.10 | +2.4% | $4.13 | $4.27 | $4.085 | 750,800 | |
| $4.15 | +0.16 | +4.0% | $3.99 | $4.205 | $3.97 | 716,600 | |
| $3.99 | -0.06 | -1.5% | $4.05 | $4.076 | $3.87 | 847,300 | |
| $4.05 | -0.08 | -1.9% | $4.08 | $4.08 | $3.93 | 372,900 | |
| $4.13 | -0.155 | -3.6% | $4.37 | $4.52 | $4.032 | 983,800 | |
| $4.285 | -0.135 | -3.1% | $4.45 | $4.565 | $4.28 | 625,900 | |
| $4.42 | -0.04 | -0.9% | $4.48 | $4.68 | $4.405 | 477,600 | |
| $4.46 | -0.06 | -1.3% | $4.54 | $4.67 | $4.38 | 734,900 | |
| $4.52 | +0.19 | +4.4% | $4.35 | $4.72 | $4.22 | 1,065,300 | |
| $4.33 | -0.08 | -1.8% | $4.40 | $4.62 | $4.23 | 1,089,700 | |
| $4.41 | -0.37 | -7.7% | $4.72 | $4.82 | $4.37 | 1,340,000 | |
| $4.78 | -0.49 | -9.3% | $5.24 | $5.26 | $4.76 | 648,300 | |
| $5.27 | -0.11 | -2.0% | $5.35 | $5.403 | $5.11 | 1,010,700 | |
| $5.38 | +0.11 | +2.1% | $5.25 | $5.61 | $5.171 | 867,900 | |
| $5.27 | -0.22 | -4.0% | $5.80 | $5.80 | $5.13 | 1,346,000 | |
| $5.49 | -0.29 | -5.0% | $5.72 | $5.795 | $5.47 | 1,241,900 | |
| $5.78 | -0.07 | -1.2% | $5.87 | $5.995 | $5.65 | 707,400 | |
| $5.85 | -0.28 | -4.6% | $6.17 | $6.17 | $5.83 | 793,000 | |
| $6.13 | -0.21 | -3.3% | $6.59 | $6.68 | $6.06 | 834,800 | |
| $6.34 | -0.48 | -7.0% | $6.80 | $6.82 | $6.25 | 802,600 | |
| $6.82 | +0.19 | +2.9% | $6.75 | $6.88 | $6.57 | 507,000 | |
| $6.63 | -0.29 | -4.2% | $6.93 | $7.05 | $6.59 | 785,800 | |
| $6.92 | -0.22 | -3.1% | $7.12 | $7.18 | $6.88 | 932,000 | |
| $7.14 | -0.31 | -4.2% | $7.50 | $7.59 | $6.97 | 708,200 | |
| $7.45 | -0.29 | -3.7% | $7.69 | $7.76 | $7.125 | 757,800 | |
| $7.74 | -0.135 | -1.7% | $7.83 | $7.98 | $7.66 | 787,300 | |
| $7.875 | +0.225 | +2.9% | $7.73 | $7.95 | $7.61 | 452,800 | |
| $7.65 | +0.17 | +2.3% | $7.51 | $7.79 | $7.42 | 499,700 | |
| $7.48 | +0.22 | +3.0% | $7.22 | $7.67 | $7.154 | 1,155,000 | |
| $7.26 | 0.00 | 0.0% | $7.26 | $7.38 | $7.03 | 992,600 | |
| $7.26 | +0.34 | +4.9% | $6.86 | $7.50 | $6.82 | 1,226,500 | |
| $6.92 | -1.16 | -14.4% | $8.08 | $8.08 | $6.325 | 3,749,600 | |
| $8.08 | -0.04 | -0.5% | $7.93 | $8.70 | $7.66 | 8,396,500 | |
| $8.12 | -0.12 | -1.5% | $8.38 | $8.495 | $7.95 | 2,347,300 | |
| $8.24 | -0.62 | -7.0% | $8.75 | $8.79 | $8.21 | 646,700 | |
| $8.86 | -1.735 | -16.4% | $10.60 | $10.72 | $8.845 | 1,003,800 | |
| $10.60 | -0.485 | -4.4% | $11.07 | $11.07 | $10.31 | 915,400 | |
| $11.08 | -0.38 | -3.3% | $11.37 | $11.45 | $11.06 | 222,500 | |
| $11.46 | -0.02 | -0.2% | $11.52 | $11.60 | $11.22 | 475,300 | |
| $11.48 | +0.20 | +1.8% | $11.27 | $11.56 | $10.60 | 664,400 | |
| $11.28 | +0.37 | +3.4% | $10.81 | $11.37 | $10.58 | 901,300 | |
| $10.91 | 0.00 | 0.0% | $10.86 | $11.00 | $10.39 | 473,600 | |
| $10.91 | -0.22 | -2.0% | $11.13 | $11.29 | $10.75 | 584,300 | |
| $11.13 | -0.17 | -1.5% | $11.28 | $11.45 | $11.11 | 325,900 | |
| $11.30 | -0.01 | -0.1% | $11.36 | $11.55 | $10.96 | 391,800 | |
| $11.31 | +0.62 | +5.8% | $10.90 | $11.35 | $10.79 | 1,281,867 | |
| $10.69 | +0.31 | +3.0% | $10.20 | $10.88 | $9.68 | 1,313,673 | |
| $10.38 | +0.54 | +5.5% | $9.97 | $10.42 | $9.895 | 604,000 | |
| $9.84 | -0.15 | -1.5% | $10.00 | $10.05 | $9.73 | 300,400 |
Splits
1 split · NASDAQ:CRBP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation |
- Ticker
- Hamburg:3371
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hamburg
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
Latest deck · Nov 16, 2026
Investor Presentation (November 2026)
Investor deck · 55 slides
Latest news
Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical trial data for CRB-913 at ObesityWeek® 2026
Nov 16, 2026
Closed $3.38 (-0.4%) on Nov 16, 2026
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
Nov 10, 2026
Closed $3.93 (+11.6%) on Nov 10, 2026
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
Nov 5, 2026
Closed $2.86 (-19.9%) on Nov 5, 2026
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
Oct 22, 2026
Closed $4.13 (-3.6%) on Oct 22, 2026
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Sep 29, 2026
Closed $6.63 (-4.2%) on Sep 29, 2026
Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity
Sep 14, 2026
Closed $8.08 (-0.5%) on Sep 14, 2026
Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity
Sep 11, 2026
Closed $8.08 (-0.5%) on Sep 14, 2026
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 17, 2026
Closed $10.49 (+4.0%) on Aug 17, 2026
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
Aug 6, 2026
Closed $9.74 (+1.8%) on Aug 6, 2026
Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity
Aug 4, 2026
Closed $9.40 (+5.4%) on Aug 4, 2026
Corbus Pharmaceuticals Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 26 in the last 12 months · 119 in all · newest Nov 16, 2026 · oldest 2019
- Calls
- 3 calls with a replay · 3 with a transcript · latest Nov 10, 2020
- Decks
- 46 decks · latest Nov 16, 2026
Where Corbus Pharmaceuticals Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRBP · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A3D54P | Lang & Schwarz | Germany | EUR |
| gettex:3371 | gettex | Germany | EUR |
| LS Exchange:A3D54P | LS Exchange | Germany | EUR |
| BOATS:CRBP | BOATS | United States | USD |
| LSE:0SZI | LSE | United Kingdom | USD |
| Tradegate:3371 | Tradegate | Germany | EUR |
| Dusseldorf:3371 | Dusseldorf | Germany | EUR |
| Frankfurt:3371 | Frankfurt | Germany | EUR |
| Hamburg:3371 · This page | Hamburg | Germany | EUR |
| Munich:3371 | Munich | Germany | EUR |
| Stuttgart:3371 | Stuttgart | Germany | EUR |
Valuation
Price/book 0.5× against a median of 4.2×: the lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$68.98M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.85
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP | US$42.45M | −US$68.98M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 1.85 |
| Spero Therapeutics, Inc. · NASDAQ:SPRO | US$43.23M | −US$63.10M | n/a | −1.5× | n/a | 55.4× | −71.0% | 2.0× | 1.68 |
| Eloxx Pharmaceuticals, Inc. · NASDAQ:ELOX | US$43.15M | −US$1.28M | n/a | n/a | n/a | 1.1× | n/a | 0.3× | n/a |
| Arecor Therapeutics PLC · LSE:AREC | US$42.37M | US$38.32M | 48.8× | 17.1× | n/a | 8.8× | 38.7% | 0.0× | n/a |
| OS Therapies Incorporated · AMEX:OSTX | US$42.00M | US$41.57M | n/a | n/a | n/a | n/a | n/a | n/a | 1.70 |
| Advagene Biopharma Co., Ltd. · TPEX:6709 | US$41.88M | US$32.02M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | n/a |
| Biomea Fusion, Inc. · NASDAQ:BMEA | US$41.75M | US$15.85M | n/a | n/a | n/a | 5.5× | n/a | 0.1× | 1.14 |
| Prescient Therapeutics Limited · ASX:PTX | US$41.64M | US$35.80M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | n/a |
| Mereo BioPharma Group plc · NASDAQ:MREO | US$41.52M | US$16.00M | n/a | 20.0× | n/a | 1.8× | n/a | 0.0× | 1.34 |
| Elicio Therapeutics, Inc. · NASDAQ:ELTX | US$41.05M | US$19.78M | n/a | n/a | n/a | 2.2× | n/a | 0.5× | 1.81 |
| MiNK Therapeutics, Inc. · NASDAQ:INKT | US$40.93M | US$33.46M | n/a | 167× | n/a | n/a | n/a | n/a | 0.81 |
| Median of the others | US$41.82M | US$25.90M | 48.8× | 18.6× | 4.2× | −16.1% | 0.1× | 1.51 |
Forecasts
9 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 33.22 USD · Analysts' mean
- EPS, year to Dec 2026
- -6.45 · 4 analysts
- Revenue, year to Dec 2026
- 1.25M · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Yuval Cohen | Chief Executive Officer and Director |
| Sean Moran | Chief Financial Officer |
| Ian Hodgson | Chief Operating Officer |
| G. Scott Goeken | General Counsel & Corporate Secretary |
| Christina Bertsch | VP of Human Resources |
| Leonardo Viana Nicacio | Chief Medical Officer |
| Nishant Saxena | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Yuval Cohen | Chief Executive Officer and Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Q3 2020 Earnings Call | Tue, Nov 10, 2020 · 8:30 AM ET | Replay |
| Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Q2 2020 Earnings Call | Thu, Aug 06, 2020 · 8:30 AM ET | Replay |
| Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Q1 2020 Earnings Call | Mon, May 11, 2020 · 8:30 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | +11.7% |
| Q2 2026 | Aug 6, 2026 · Before open | +1.8% |
| Q1 2026 | May 12, 2026 · Before open | +3.5% |
| Q4 2025 | Mar 9, 2026 | +25.3% |
| Q3 2025 | Nov 12, 2025 · Before open | +7.4% |
| Q2 2025 | Aug 5, 2025 · Before open | −4.7% |
| Q1 2025 | May 6, 2025 · Before open | −15.8% |
| Q4 2024 | Mar 10, 2025 · Before open | 0.0% |
| Q3 2024 | Nov 7, 2024 · Before open | −2.1% |
| Q2 2024 | Aug 6, 2024 · Before open | −3.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · Before open | +2.5% |
| Q4 2023 | Mar 12, 2024 · Before open | +16.5% |
| Q3 2023 | Nov 7, 2023 · Before open | −16.7% |
| Q2 2023 | Aug 8, 2023 · Before open | −0.2% |
| Q1 2023 | May 9, 2023 · After close | +5.0% |
| Q4 2022 | Mar 7, 2023 · Before open | −6.7% |
| Q3 2022 | Nov 8, 2022 · After close | −2.3% |
| Q2 2022 | Aug 9, 2022 · After close | +0.0% |
| Q1 2022 | May 10, 2022 · Before open | −2.7% |
| Q4 2021 | Mar 8, 2022 · Before open | +7.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2026) | Investor deck | 55 slides | Nov 16, 2026 |
| Investor Presentation (October 2026) | Investor deck | 62 slides | Oct 15, 2026 |
| Investor Presentation (September 2026) | Investor deck | 58 slides | Sep 14, 2026 |
| Investor Presentation (May 2026) | Investor deck | 58 slides | May 26, 2026 |
| Investor Presentation (March 2026) | Investor deck | 63 slides | Mar 9, 2026 |
| Investor Presentation (February 2026) | Investor deck | 61 slides | Feb 25, 2026 |
| Investor Presentation (January 2026) | Investor deck | 59 slides | Jan 12, 2026 |
| Investor Presentation (December 2025) | Investor deck | 54 slides | Dec 11, 2025 |
| Investor Presentation (October 2025) | Investor deck | 50 slides | Oct 20, 2025 |
| Investor Presentation (May 2025) | Investor deck | 55 slides | May 19, 2025 |
All 46 decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$75M raised · Jefferies LLC +1 Dealers: Jefferies LLC (co-lead), Piper Sandler & Co. (co-lead) Use of proceeds: Fund clinical development of its pipeline, working capital and general corporate purposes | Nov 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 881.7K | 3.94M | 36.1M | 4.82M | 2.44M | 1.91M |
| Cost of revenue | 233.0K | 600.0K | 31.2M | 1.49M | 1.64M | 98.3K | 89.6M | 48.6M | 26.0M | 15.4M |
| Gross profit | -233.0K | -600.0K | -31.2M | -1.49M | -757.5K | 3.94M | -53.5M | -43.8M | -23.6M | -13.5M |
| Research and development | 70.1M | 32.2M | 31.2M | 16.1M | 36.4M | 98.3M | 89.6M | 48.6M | 26.0M | 15.4M |
| Selling, general and administrative | 15.2M | 16.5M | 13.9M | 18.7M | 20.4M | 28.5M | 23.6M | 13.0M | 8.96M | 6.46M |
| Operating income | -85.3M | -48.7M | -45.1M | -39.8M | -56.0M | -122.8M | -77.1M | -56.7M | -32.6M | -20.0M |
| Depreciation and amortization | 233.0K | 588.0K | 641.0K | 763.0K | 999.8K | 1.12M | 739.4K | 493.9K | 255.7K | 87.7K |
| EBITDA | -85.1M | -48.1M | -44.4M | -39.1M | -55.0M | -121.7M | -76.4M | -56.3M | -32.3M | -19.9M |
| Interest expense | 0 | 1.87M | 3.86M | 3.10M | 2.71M | 1.13M | 0 | 0 | 3.63K | 3.12K |
| Income before tax | -78.5M | -40.2M | -44.6M | -42.3M | -45.6M | -111.3M | -71.5M | -55.7M | -32.4M | -20.0M |
| Income tax | 0 | 0 | 13.5M | -87.8K | 35.0K | -2.30M | 1.08M | -396.9K | 13.6K | |
| Net income | -78.5M | -40.2M | -44.6M | -42.3M | -45.6M | -111.3M | -71.5M | -55.7M | -32.4M | -20.0M |
| Earnings per share, basic | -5.90 | -3.68 | -10.31 | -10.15 | -11.15 | -1.42 | -1.12 | -0.98 | -0.65 | -0.49 |
| Earnings per share, diluted | -5.90 | -3.68 | -10.31 | -10.15 | -11.15 | -1.42 | -1.12 | -0.98 | -0.65 | -0.49 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 28.5M | 17.2M | 13.7M | 17.0M | 25.0M | 85.4M | 31.7M | 41.7M | 62.5M | 15.0M |
| Short-term investments | 134.8M | 131.9M | 7.18M | 42.2M | 72.6M | 0 | 159.0K | 150.0K | ||
| Receivables | 1.50M | 2.58M | 2.68M | 1.33M | ||||||
| Inventory | 350.0K | -2.68M | 0 | 0 | ||||||
| Current assets | 167.0M | 153.0M | 23.5M | 60.2M | 100.2M | 92.1M | 38.2M | 44.2M | 65.5M | 17.4M |
| Property, plant and equipment | 159.0K | 385.0K | 973.0K | 1.61M | 2.39M | 4.07M | 5.08M | 2.71M | 1.43M | 435.3K |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 168.2M | 155.9M | 28.3M | 66.3M | 107.7M | 102.3M | 49.1M | 47.0M | 67.0M | 17.9M |
| Accounts payable | 2.21M | 4.79M | 3.18M | 2.17M | 1.78M | 7.38M | 11.1M | 6.35M | 3.13M | 3.42M |
| Current liabilities | 20.7M | 11.8M | 31.9M | 12.6M | 17.0M | 31.9M | 34.9M | 18.1M | 8.20M | 8.90M |
| Long-term debt | 0 | 16.0M | 15.6M | 18.0M | 0 | 5.00K | ||||
| Total debt | 1.63M | 3.24M | 17.9M | 21.6M | 21.2M | 21.2M | 9.45M | 394.3K | 332.9K | 276.4K |
| Total liabilities | 20.7M | 13.5M | 35.2M | 33.3M | 38.6M | 57.0M | 43.0M | 19.5M | 9.19M | 8.97M |
| Shareholders' equity | 147.5M | 142.4M | -6.91M | 33.0M | 69.1M | 45.3M | 6.16M | 27.5M | 57.8M | 8.92M |
| Shares outstanding | 17.6M | 12.2M | 4.42M | 4.17M | 4.17M | 98.9M | 64.7M | 57.2M | 55.6M | 44.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -64.5M | -41.8M | -36.1M | -37.5M | -48.2M | -99.7M | -45.7M | -30.1M | -27.8M | -13.6M |
| Capital spending | -7.00K | 0 | 0 | -13.4K | -54.2K | -484.5K | -2.74M | -2.30M | -707.4K | -353.0K |
| Free cash flow | -64.5M | -41.8M | -36.1M | -37.6M | -48.2M | -100.2M | -48.5M | -32.4M | -28.5M | -13.9M |
| Cash from investing | -1.64M | -121.3M | 35.6M | 30.1M | -73.4M | -484.5K | -2.74M | -2.30M | -707.4K | -353.0K |
| Cash from financing | 77.4M | 166.6M | -2.82M | -533.6K | 60.8M | 154.9M | 38.5M | 11.4M | 76.0M | 16.7M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 142.2M | 40.7M | 12.1M | 78.9M | 16.7M | |||||
| Change in cash | 11.3M | 3.47M | -3.28M | -8.00M | -60.8M | 54.7M | -10.00M | -20.9M | 47.5M | 2.82M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Aug 7, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| 3 · Initial statement of ownership | Aug 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 27, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 6, 2026 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Jun 17, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 29, 2026 | Offer document | SEC |
| 8-K · Current report | May 26, 2026 | Current report | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 21, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 16, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 14, 2026 | Current report | SEC |
| 8-K · Current report | Apr 7, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 2, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2026 | Meeting notice | SEC |
| 424B3 · Prospectus | Mar 25, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 23, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 18, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 13, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 11, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 2, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 25, 2026 | Current report | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 15, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 11, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Nov 3, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2025 | Current report | SEC |
| 424B5 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| 8-K · Current report | Sep 16, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 16, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 19, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 1, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 1, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 1, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 21, 2025 | Management or board change | SEC |
| 3 · Initial statement of ownership | Mar 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 18, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 11, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 14, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 14, 2025 | Current report | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 8-K · Current report | Nov 15, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 11, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 24, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 6, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 14, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jun 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | May 31, 2024 | Offer document | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2024 | Insider trade | SEC |
| 8-K · Current report | May 20, 2024 | Management or board change | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | May 8, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 11, 2024 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 10, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 10, 2024 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 2, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 2, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 2, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Mar 22, 2024 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 21, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 20, 2024 | Current report | SEC |
| 10-K/A · Annual report, amended | Mar 20, 2024 | Annual report | SEC |
| 424B3 · Prospectus | Mar 20, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 18, 2024 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | Mar 18, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 15, 2024 | Other filings | SEC |
| S-3 · Registration statement | Mar 13, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 29, 2024 | Insider trade | SEC |
This page holds 200 of 812 filings. Open Filings
Cap table
Built by 6ix from Corbus Pharmaceuticals Holdings, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 20,606,760
- Fully diluted
- 20,606,760
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 20,606,760 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 20,606,760 |
| Sep 30, 2026 | 20,606,760 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| George Golumbeski Other companies: Acumen Pharmaceuticals, Inc. (Chairman of its Board of Directors · Since at least Nov 6, 2025); Mural Oncology plc (Director · Since at least Jul 30, 2024); Shattuck Labs, Inc. (Director · Since at least Oct 8, 2020); Sage Therapeutics Inc (Director · Since at least Jan 22, 2019); Enanta Pharmaceuticals, Inc. (Director · Feb 7, 2014 – Feb 26, 2020 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past) | Director · Jul 6, 2020 – Jul 6, 2020 · Past |
| Rachelle Jacques Other companies: uniQure N.V. (Director · Since at least Oct 21, 2021); Akari Therapeutics PLC (Chief Executive Officer, Director · Jan 1, 2024 – Apr 26, 2024 · Past); Viela Bio Inc (Director · Mar 15, 2021 – Mar 15, 2021 · Past) | Director · Since at least Jun 17, 2021 |
| Winston Kung Other companies: ArriVent BioPharma, Inc. (Chief Financial Officer · Since at least Jan 25, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022); PMV Pharmaceuticals, Inc. (COO, CFO · Sep 24, 2020 – May 12, 2023 · Past) | Director · Since at least Aug 16, 2024 |
| Avery W Catlin Other companies: Provention Bio Inc (Director · Sep 5, 2018 – Apr 27, 2023 · Past); Celldex Therapeutics, Inc. (Sr. VP & CFO · Jan 6, 2006 – Sep 2, 2016 · Past) | Director · Nov 24, 2014 – May 30, 2024 · Past |
| Brent Pfeiffenberger Other companies: Century Therapeutics, Inc. (President and CEO, Director · Since at least Dec 4, 2023); Butterfly Network, Inc. (President and CEO, Director · Mar 7, 2024 – Mar 7, 2024 · Past) | Director · Since at least May 13, 2026 |
| David P. Hochman Other companies: Orchestra BioMed Holdings, Inc. (See Remarks, Director · Since at least Jan 26, 2023); Motus GI Holdings, Inc. (Director · Feb 13, 2018 – Feb 13, 2019 · Past) | Director · Nov 10, 2017 – May 20, 2020 · Past |
| Renu Gupta Other companies: Insmed Incorporated (Executive Vice President & CMO · Dec 1, 2010 – Jan 31, 2014 · Past); Agenus Inc. (Sr. VP Development · Feb 24, 2006 – Jul 20, 2006 · Past) | Director · Nov 24, 2014 – May 25, 2017 · Past |
| Sean Moran Other companies: InVivo Therapeutics Holdings Corp (Acting Chief Financial Officer · Aug 22, 2013 – Sep 3, 2013 · Past); Imunon, Inc. (Chief Financial Officer · Dec 2, 2008 – Mar 17, 2009 · Past) | Chief Financial Officer · Since at least Nov 24, 2014 |
| Dominic Smethurst Other companies: Bicycle Therapeutics PLC (Chief Medical Officer · Aug 10, 2020 – Jan 3, 2023 · Past) | Chief Medical Officer · Since at least Feb 27, 2024 |
| John Kenneth Jenkins Other companies: Provention Bio Inc (Director · Aug 10, 2020 – Apr 27, 2023 · Past) | Director · Since at least Jun 5, 2018 |
All 26 people
| Person | Seat |
|---|---|
| Leonardo Viana Nicacio Other companies: Protara Therapeutics, Inc. (Chief Medical Officer · Since at least Apr 15, 2025) | Chief Medical Officer · Since Jul 6, 2026 |
| Paris Panayiotopoulos Other companies: The Medicines Company (Director · May 30, 2019 – Jan 6, 2020 · Past) | Director · May 22, 2019 – May 22, 2019 · Past |
| Peter Salzmann Other companies: Immunovant, Inc. (Chief Executive Officer, Director · Dec 18, 2019 – Apr 16, 2025 · Past) | Director · Mar 6, 2020 – May 30, 2024 · Past |
| Yong Ben Other companies: BridgeBio Oncology Therapeutics, Inc. (Chief Medical and Development Officer · Since at least Aug 11, 2025) | Director · Since at least Mar 6, 2023 |
| Alan F Holmer | Director · Since at least May 18, 2022 |
| Anne Altmeyer | Director · Since at least Sep 26, 2022 |
| Barbara White | Chief Medical Officer · Nov 24, 2014 – Feb 2, 2021 · Past |
| Christina Bertsch | VP of Human Resources · Since at least Nov 5, 2026 |
| Craig Stuart Millian | Chief Operating Officer · Feb 2, 2021 – Feb 13, 2023 · Past |
| G. Scott Goeken | General Counsel & Corporate Secretary · Since at least Nov 5, 2026 |
| Ian Hodgson | Chief Operating Officer · Since at least Mar 13, 2025 |
| Mark Tepper | President and CSO · Nov 24, 2014 – Jan 18, 2019 · Past |
| Nishant Saxena | Chief Business Officer · Since at least May 21, 2026 |
| Rachael Louise Brake | Chief Scientific Officer · Dec 6, 2021 – Feb 13, 2023 · Past |
| Robert Paul Discordia | Chief Operating Officer · Aug 6, 2019 – Mar 17, 2020 · Past |
| Yuval Cohen | Chief Executive Officer and Director · Since at least Nov 10, 2017 |
Log in to ask 6ix AI your own questions about Corbus Pharmaceuticals Holdings, Inc.